Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P31371
UPID:
FGF9_HUMAN
Alternative names:
Glia-activating factor; Heparin-binding growth factor 9
Alternative UPACC:
P31371; A8K427; Q3SY32
Background:
Fibroblast growth factor 9 (FGF9), also known as Glia-activating factor or Heparin-binding growth factor 9, plays a pivotal role in embryonic development, cell proliferation, differentiation, and migration. Its involvement extends to the regulation of glial cell growth, brain tissue repair, neuronal cell differentiation, and the stimulation of glial tumors.
Therapeutic significance:
FGF9's link to Multiple synostoses syndrome 3, a bone disease marked by joint fusions and progressive deafness, underscores its therapeutic potential. Targeting FGF9 could lead to innovative treatments for this syndrome and possibly other related disorders.